Skip to content

Medicine Matters

Sharing successes, challenges and daily happenings in the Department of Medicine

Medicine Matters Home › Article of the Week

Article of the Week

Associations of Routinely Collected Measures of Socioeconomic Disadvantage With Longitudinal Care Continuum Outcomes in a Clinical Cohort of Persons With HIV in the United States

 ARTICLE: Associations of Routinely Collected Measures of Socioeconomic Disadvantage With Longitudinal Care Continuum Outcomes in a Clinical Cohort of Persons With HIV in the United… Read More »Associations of Routinely Collected Measures of Socioeconomic Disadvantage With Longitudinal Care Continuum Outcomes in a Clinical Cohort of Persons With HIV in the United States

Phone-based screening versus home-based screening after tuberculosis in India (TB Aftermath): a multicentre, open-label, randomised, controlled, non-inferiority trial

ARTICLE: Phone-based screening versus home-based screening after tuberculosis in India (TB Aftermath): a multicentre, open-label, randomised, controlled, non-inferiority trial AUTHORS: Samyra R Cox, Abhay Kadam, Shahanara Valawalkar, Gayatri… Read More »Phone-based screening versus home-based screening after tuberculosis in India (TB Aftermath): a multicentre, open-label, randomised, controlled, non-inferiority trial

Strength-Based Exercise Is Not Associated With Ventricular Arrhythmia in Arrhythmogenic Cardiomyopathy-Towards Safer Exercise Options

ARTICLE: Strength-Based Exercise Is Not Associated With Ventricular Arrhythmia in Arrhythmogenic Cardiomyopathy-Towards Safer Exercise Options AUTHORS: Katia Chiampas, Steven A Muller, Evans Osuji, Alan P Jacobsen, Lisa R Yanek, Richard… Read More »Strength-Based Exercise Is Not Associated With Ventricular Arrhythmia in Arrhythmogenic Cardiomyopathy-Towards Safer Exercise Options

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

ARTICLE: A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial AUTHORS: John Z Metcalfe, Isabelle R… Read More »A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

Real-World Experience with an Electronic Patient-Reported Outcome Measure in Care of Patients with Non-Dialysis-Dependent CKD

ARTICLE: Real-World Experience with an Electronic Patient-Reported Outcome Measure in Care of Patients with Non-Dialysis-Dependent CKD AUTHORS: Dipal M Patel, Dingfen Han, Mary Ann C… Read More »Real-World Experience with an Electronic Patient-Reported Outcome Measure in Care of Patients with Non-Dialysis-Dependent CKD

Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19

ARTICLE: Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19 AUTHORS: Karan Srisurapanont, Kasama Manothummetha, Nirada Siriyakorn, Mary G Bowring, Lucy X Li, Willa V Cochran, Cory… Read More »Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19

Elimination of senescent cells with senolytic drugs as adjunctive host-directed therapy reduces tuberculosis progression in mice

ARTICLE: Elimination of senescent cells with senolytic drugs as adjunctive host-directed therapy reduces tuberculosis progression in mice AUTHORS: Somnath Shee, Yazmin B Martinez-Martinez, Benjamin Koleske,… Read More »Elimination of senescent cells with senolytic drugs as adjunctive host-directed therapy reduces tuberculosis progression in mice